GO
Loading...

Enter multiple symbols separated by commas

Stocks Amgen Inc

More

  • NEW YORK, Sept 2- A U.S. appeals court has cleared the way for Novartis AG to launch the first biosimilar drug in the United States as it declined on Wednesday to stop the sale of the company's copycat version of Amgen Inc's blockbuster cancer drug Neupogen. Amgen had sought an injunction while both companies ask the court to clarify federal regulations on when...

  • NEW YORK, Sept 2- A U.S. appeals court has cleared the way for Novartis AG to launch the first biosimilar drug in the United States as it declined on Wednesday to stop the sale of the company's copycat version of Amgen Inc's blockbuster cancer drug Neupogen. The U.S. Court of Appeals for the Federal Circuit in July said Novartis could begin to market its biosimilar...

  • NEW YORK, Sept 2- A U.S. appeals court has cleared the path for Novartis AG to launch the first biosimilar drug in the United States as it declined on Wednesday to stop the sale of the company's copycat version of Amgen Inc's blockbuster cancer drug Neupogen. The U.S. Court of Appeals for the Federal Circuit in July said Novartis could begin to market its biosimilar...

  • *China intervention helping calm market jitters- traders. LONDON, Sept 2- European equities gained on Wednesday after a volatile start to the week, drawing support from brokerage measures in China to invigorate the country's battered markets and from expectations of policy-easing by major central banks. "Possible actions by some central banks such as China...

  • *China intervention helping calm market jitters- traders. *Alstom up on report GE deal set for green light. China, the epicenter of worries over the global growth outlook, enjoyed a late market recovery after nine Chinese brokerages pledged to buy more than 30 billion yuan of shares, according to the China Securities Journal.

  • GENEVA— Swiss drug maker Novartis says it will cooperate with California- based biotech giant Amgen to develop and sell neuroscience treatments for illnesses and ailments like Alzheimer's disease and migraine headaches. A Novartis statement released late Tuesday said that as part of the deal, Amgen will make initial payments and cover some research and...

  • After-hours buzz: H&R Block, Anheuser-Busch & more Tuesday, 1 Sep 2015 | 5:48 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Tuesday: H&R Block, Guidewire, Anheuser-Busch & more.

  • Sept 1- Amgen Inc said its experimental bone drug was found to be more effective than an already marketed drug in a late-stage study. Amgen's drug, romosozumab, met the main goal of showing a significant difference over Eli Lilly& Co's teriparatide in improving total hip bone density by the 12th month in postmenopausal women with osteoporosis.

  • Amgen's bone drug succeeds in late-stage study Tuesday, 1 Sep 2015 | 4:49 PM ET

    Sept 1- Amgen Inc said its experimental bone drug was found to be more effective than an already marketed drug in a late-stage study. Amgen's drug, romosozumab, met the main goal of showing a significant difference over teriparatide in improving total hip bone density by the 12th month in postmenopausal women with osteoporosis. Osteoporosis is a condition...

  • LONDON, Sept 1- Novartis and Amgen are joining forces in the hunt for an Alzheimer's treatment, in the latest sign that drugmakers believe an effective therapy for the memory-robbing disease may be within reach. Swiss-based Novartis said on Tuesday the alliance was part of a drive to build up its portfolio in neuroscience, following other deals this summer that...

  • NEW YORK— Canadian drugmaker Valeant will work with British competitor AstraZeneca on a potential treatment for psoriasis a few months after biotech giant Amgen said it was ending research on the drug because of a link to suicidal thoughts and behavior. Valeant could pay AstraZeneca as much as $445 million if the drug is successfully developed and approved...

  • Early movers: AAL, DAL, FDX, FCX, AAPL & more Tuesday, 1 Sep 2015 | 7:44 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Sept 1- Canada's Valeant Pharmaceuticals International Inc is buying rights to AstraZeneca Plc's late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc in May. Valeant said on Tuesday it would make an upfront payment of $100 million to AstraZeneca, and additional pre-launch milestone payments of up to $170 million and...

  • NEW YORK— Shares of The Medicines Co. surged in premarket trading Monday after the company and its partner Alnylam Pharmaceuticals Inc. reported study results suggesting effectiveness for a potential cholesterol drug. Shares of Medicines jumped $5.98, or 17.8 percent, to $39.62 in premarket trading. Regeneron Pharmaceuticals Inc. and Sanofi sell...

  • Results with Alnylam Pharmaceuticals and Medicines Co's experimental product ALN-PCSsc highlight the competition for a market tipped to generate billions of dollars in sales. Amgen's Repatha and a rival product, Praluent, from Sanofi and Regeneron Pharmaceuticals, are each expected to generate more than $2 billion a year in sales by 2020, according to...

  • WASHINGTON, Aug 27- The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those at high risk of cardiovascular disease. Last month the FDA approved a similar drug from Regeneron Pharmaceuticals Inc and Sanofi SA. The drugs are expected to generate more than $2 billion a...

  • FDA approves Amgen's cholesterol drug Thursday, 27 Aug 2015 | 5:22 PM ET
    FDA approves Amgen's cholesterol drug

    Amgen is getting approval by the FDA for a new cholesterol drug, reports CNBC's Meg Tirrell.

  • Amgen wins approval for second biotech cholesterol drug Thursday, 27 Aug 2015 | 5:18 PM ET

    WASHINGTON— Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that have been used for decades. Thousand Oaks, California- based Amgen priced the drug slightly below a similar drug Praluent, which costs $14,600 per year. Sanofi and partner...

  • FDA lays out proposal for naming lower-cost biotech drugs Thursday, 27 Aug 2015 | 10:33 AM ET

    But representatives for the generic drug industry warned that the FDA's proposal could curb those savings by making the drugs more difficult to prescribe. For decades, they have not faced generic competition because the FDA lacked a system to approve cheaper versions until 2012. Earlier this year the agency approved the first "biosimilar."

  • Cholesterol drug wars: Amgen Thursday, 27 Aug 2015 | 6:28 AM ET
    Cholesterol drug wars: Amgen

    The FDA is expected to decide today whether to approve Amgen's cholesterol drug, Repatha, reports CNBC's Meg Tirrell.